Effect of acute and repeated treatment with desipramine or methylphenidate on serial reversal learning in rats.
Administration of stimulant and non-stimulant drugs that inhibit monoamine reuptake is known to improve cognitive and behavioral symptoms of attention deficit hyperactivity disorder (ADHD). Although this may reflect acute actions of these drugs, clinical observations suggest that prolonged treatment with these agents may result in a better therapeutic outcome. In the current study, we compared the effects of acute and repeated treatment with the stimulant drug, methylphenidate (MPH), and the non-stimulant norepinephrine reuptake inhibitor desipramine (DMI) in rats performing a reversal learning task meant to study behavioral flexibility in rats. Furthermore, we tested the effect of an acute challenge administration with these agents or vehicle on reversal performance of rats repeatedly treated with the drug or vehicle. Our results suggest the acute and repeated treatment with DMI improves reversal learning performance in a qualitatively and quantitatively similar manner. Further repeated treatment with DMI seems to produce a reversal learning improvement that persists at least 24 h after drug administration. Repeated MPH treatment only improved performance in the first within session reversal administered, suggesting that its beneficial effects may depend upon the complexity of the reversal condition tested. The differential outcome produced by stimulant and non-stimulant medications in this study may be explained in light of their distinct actions on brain catecholaminergic systems.
Seu
Emanuele
E
Department of Psychology, University of California Los Angeles, PO Box 951563, Los Angeles, CA 90095-1563, USA.
Jentsch
J David
JD
D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000494:pharmacology*; D003891:Desipramine / Q000494:pharmacology*; D004193:Discrimination Learning / Q000187:drug effects; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D020318:Rats, Long-Evans; D011930:Reaction Time; D012193:Reversal Learning / Q000187:drug effects*; D012691:Serial Learning / Q000187:drug effects*; D013997:Time Factors
D018759:Adrenergic Uptake Inhibitors; D000697:Central Nervous System Stimulants; D008774:Methylphenidate; D003891:Desipramine
Psychopharmacology (Berl). 2004 Sep;175(3):319-30
15138760
J Neurosci. 2002 Jan 15;22(2):389-95
11784783
Neuropsychopharmacology. 2002 Nov;27(5):699-711
12431845
J Abnorm Child Psychol. 1995 Aug;23(4):411-37
7560554
J Am Acad Child Adolesc Psychiatry. 1995 Jul;34(7):886-96
7649959
J Child Adolesc Psychopharmacol. 2001 Fall;11(3):251-65
11642475
Neurosci Lett. 2002 Aug 16;328(3):319-21
12147334
Psychopharmacology (Berl). 2009 Jan;202(1-3):505-19
18604598
J Neurosci Methods. 2007 Jun 15;163(1):83-91
17400296
Biol Psychiatry. 2005 Mar 1;57(5):456-63
15737659
Arch Gen Psychiatry. 2002 Jul;59(7):649-56
12090818
J Psychopharmacol. 2003 Sep;17(3):332-6
14513926
Cereb Cortex. 2007 Jun;17(6):1364-75
16920883
Psychopharmacology (Berl). 2009 Jan;202(1-3):497-504
18535818
Neuropharmacology. 2006 May;50(6):755-60
16427661
Biol Psychiatry. 2007 Jun 15;61(12):1361-9
16950217
Biol Psychiatry. 2006 Nov 15;60(10):1111-20
16806100
Pharmacol Biochem Behav. 2007 Oct;87(4):426-33
17599397
Behav Brain Funct. 2005 Oct 03;1:16
16202140
Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93
10414438
Science. 2006 Feb 10;311(5762):861-3
16469930
J Child Psychol Psychiatry. 2006 Nov;47(11):1184-94
17076758
Neuropsychopharmacology. 2008 Apr;33(5):1028-37
17637611
Neuropsychopharmacology. 2006 Nov;31(11):2376-83
16855530
Neuropsychopharmacology. 2008 Dec;33(13):3190-200
18418364
J Neurosci. 2009 Apr 15;29(15):4690-6
19369539
J Clin Psychopharmacol. 2004 Feb;24(1):30-5
14709944
J Neurochem. 2006 Jan;96(2):473-81
16336224
Biol Psychiatry. 2003 Dec 15;54(12):1465-8
14675812
J Child Adolesc Psychopharmacol. 2001 Spring;11(1):25-34
11322742
J Neurosci. 2000 Mar 15;20(6):RC65
10704519
Am J Psychiatry. 1998 May;155(5):693-5
9585725
Nature. 1996 Mar 7;380(6569):69-72
8598908
J Abnorm Child Psychol. 2003 Feb;31(1):105-20
12597703
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):34-41
17714843
Neuroreport. 2002 Dec 20;13(18):2453-7
12499848
J Neurochem. 1997 May;68(5):2032-7
9109529
Brain Res. 2002 May 17;936(1-2):58-67
11988230
J Abnorm Child Psychol. 2000 Jun;28(3):227-35
10885681
J Child Adolesc Psychopharmacol. 2005 Aug;15(4):664-70
16190797
Neuropsychopharmacology. 2007 May;32(5):1000-10
17077810
Neuropsychopharmacology. 2007 Jul;32(7):1583-99
17164816
J Neurochem. 2004 Nov;91(3):683-93
15485498
Psychopharmacology (Berl). 2007 Jun;192(2):193-206
17277934
J Abnorm Child Psychol. 1995 Apr;23(2):235-66
7642836
Behav Brain Res. 2007 May 16;179(2):219-28
17337305
J Child Psychol Psychiatry. 2004 Feb;45(2):293-305
14982243
J Psychopharmacol. 2000;14(3):299-302
11106312
Psychol Med. 1999 May;29(3):527-38
10405075
J Neurosci. 2003 Feb 1;23(3):1066-71
12574437
J Abnorm Child Psychol. 1989 Oct;17(5):473-91
2681316
Biol Psychiatry. 2007 Nov 1;62(9):977-84
17644072